Whether specific genetic feature predicted immunotherapy efficacy: A case report

Jun Chen,Linrong Pang,Lianxiang He,Ting Li,Xiaochun Cheng
DOI: https://doi.org/10.1097/md.0000000000036922
IF: 1.6
2024-01-13
Medicine
Abstract:Cervical cancer is a malignant tumor with a high incidence rate. It is estimated that 111,820 women will be diagnosed with cervical cancer in China by 2022, and 61,579 will die. [ 1 ] Generally, chemoradiation and brachytherapy are recommended for patients with locally advanced diseases. Programmed cell death-ligand 1 (PD-L1)-positive recurrent or refractory cervical cancer patients are recommended a combination of bevacizumab and chemotherapy, with a median overall survival of up to 17 months. [ 2 , 3 ]
medicine, general & internal
What problem does this paper attempt to address?